Company Overview and News

 
TTG Fintech Ltd in deal to sell its payments technology in China

2016-06-15 proactiveinvestors.com.au
TTG Fintech Ltd (ASX:TUP) has signed an agreement with Hong Kong listed Kingdee International Software Group (HKG:0268) to sell its payments solution for financial electronic authentication into China. The technology provides a solution for clearing and settlement for multi parties and TTG will provide its payment solutions to Kingdee’s cloud warehousing and cloud accounting functions. Sydney based TTG has developed the proprietary financial electronic authentication technology, and ‘Tlinx’, a cloud-supported point of sales (POS) system.
Upvote Downvote

 
Appendix 4C

2016-04-28 asx.com.au
Upvote Downvote

 
Appendix 4C

2016-01-29 asx.com.au
Upvote Downvote

 
How To Build A Dividend House: Which Stocks Go Where?

2016-01-05 seekingalpha
In response to a question about how I build our Dividend House DGI portfolio, I decided to review our classification of each stock.As part of this analysis, I u
Upvote Downvote

 
Conservative Total Return Portfolio Poised For Successful 2016

2016-01-05 seekingalpha
Deviated from core principals and got greedy; Mr. Market taught me a lesson!I expect 10%+ total return in 2016.Great opportunities in portfolio's out-of-favor s
Upvote Downvote

 
Appendix 4C

2015-10-30 asx.com.au
Upvote Downvote

 

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...